Global Antibiotic Research and Development Partnership (GARDP)

What Global Antibiotic Research and Development Partnership (GARDP) does

GARDP (Global Antibiotic Research and Development Partnership) is a Swiss not-for-profit foundation established in 2016 by the World Health Organization and DNDi (Drugs for Neglected Diseases initiative), headquartered in Geneva with a regional office (GARDP Africa) in Cape Town. The organization applies a Product Development Partnership (PDP) model to develop and deliver antibiotic treatments for serious bacterial infections, neonatal sepsis, sexually transmitted infections, and drug-resistant infections, with explicit focus on populations in low- and middle-income countries. Its core portfolio includes NUZOLVENCE (zoliflodacin) — a first-in-class single-dose oral antibiotic approved by the US FDA in December 2025 for uncomplicated urogenital gonorrhea — the Cefiderocol Access Program for severe Gram-negative infections, Neox-121 in clinical development with Lixa Pty Ltd, and the NeoOBS neonatal sepsis clinical trial. GARDP runs seven programs (Serious Bacterial Infections & Sepsis, Neonatal Sepsis, STIs, Discovery & Exploratory Research, Access to Antibiotics, SECURE for pandemic preparedness, and the REVIVE scientific collaboration platform) and works with more than 60 partners across over 20 countries.

GARDP does not develop proprietary technology platforms; instead, it manages clinical development programs and orchestrates licensing and sublicensing with pharmaceutical and biotech partners (Shionogi, Debiopharm, Orchid Pharma, Antabio, Lixa) to make treatments available in LMICs. Its go-to-market relies on public-private partnerships with pharmaceutical companies, governments (Japan, European Commission), and global health NGOs (CHAI, DNDi, MMV, CARB-X), delivering antibiotics through licensing and sublicense agreements rather than direct sales.

As a not-for-profit, GARDP is funded primarily through grants from governments, foundations, and institutional donors; the Executive Director has mobilized over €180 million in funding cumulatively. Revenue figures are not publicly disclosed, pricing of treatments is governed by access-focused licensing agreements rather than market pricing, and customer / beneficiary populations are patient groups in LMICs reached through partner health systems rather than purchasing customers. The publicly stated intent is to "slash delays in access to antibiotics from decades to years."

Name

Global Antibiotic Research and Development Partnership (GARDP)

Legal name

Global Antibiotic Research and Development Foundation

Website

https://gardp.org

Company type

Private

Founded year

2016

Operating status

Operating

Short description

GARDP is a Swiss not-for-profit foundation established in 2016 that develops and delivers antibiotic treatments for drug-resistant infections, neonatal sepsis, gonorrhea, and serious bacterial infections, primarily serving patients in low- and middle-income countries through public-private partnerships and licensing agreements with pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Infectious Disease Drug Development

NAICS

Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Antibiotic drug development
• Antimicrobial resistance research
• Global public health partnerships
• Clinical trial programs
• Access to medicines

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Donor Funding and Grants: As a not-for-profit global health organization, GARDP operates primarily through funding from governments, foundations, and international organizations. The organization mobilizes resources from public and private sector donors to fund R&D and access programs.

Distribution channels3 records

Marketing channels5 records

Core offering

GARDP is a not-for-profit Product Development Partnership (PDP) that develops new antibiotic treatments and expands access to existing antibiotics for populations that traditional pharmaceutical markets do not serve. Its portfolio includes FDA-approved NUZOLVENCE (zoliflodacin) for gonorrhea, the clinical-stage candidate Neox-121, and access initiatives such as the Cefiderocol Access Program. The organization coordinates multi-country Phase 3 clinical trials, licensing, and sublicense agreements to deliver treatments for serious bacterial infections, neonatal sepsis, sexually transmitted infections, and drug-resistant Gram-negative infections.

Product overview

GARDP is a not-for-profit global health organization that develops antibiotic treatments through multiple specialized programs rather than a single product. Its portfolio includes drug treatments (NUZOLVENCE/zoliflodacin for gonorrhea, cefiderocol partnership for Gram-negative infections, neox-121 in clinical trials) organized under thematic programs: Serious Bacterial Infections & Sepsis, Neonatal Sepsis, Sexually Transmitted Infections, Discovery & Exploratory Research, Access to Antibiotics, SECURE (pandemic preparedness), and REVIVE (scientific collaboration platform). The organization operates through public-private partnerships to deliver treatments for populations that traditional markets cannot serve, working toward its '5by2025' initiative.

Differentiator

Problem solved

Functional benefit

Products and services

• NUZOLVENCE (zoliflodacin) A first-in-class, single-dose oral antibiotic developed for treating uncomplicated urogenital gonorrhea in adults and adolescents. Approved by the U.S. FDA in December 2025 based on Phase 3 clinical trial data from five countries.
• Cefiderocol Access Program A partnership initiative with Shionogi & Co. and the Clinton Health Access Initiative to expand global access to cefiderocol, an antibiotic for severe Gram-negative bacterial infections, particularly in low- and middle-income countries.
• Neox-121

Quantifiable outcome

• 79 novel health tools delivered to 2.4 billion people over nearly 30 years by PDPs including GARDP
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Ten partnerships are on record, tiered core and major.

• Orchid PharmacoreStrategic or Co-development Partner · 12 October 2023In October 2023, GARDP and Orchid Pharma signed a sublicense agreement for the production and supply of cefiderocol in low- and middle-income countries. This agreement was signed in collaboration with the Clinton Health Access Initiative.
• Shionogi & Co. Ltd.coreStrategic or Co-development Partner · 1 June 2023In June 2023, Japan's Shionogi partnered with GARDP and the Clinton Health Access Initiative to expand global access to cefiderocol, an antibiotic for severe Gram-negative bacterial infections. This partnership aims to ensure antibiotic availability in low- and middle-income countries.
• Clinton Health Access Initiative (CHAI)coreStrategic or Co-development Partner · 1 June 2023Partnership with GARDP and Shionogi to expand global access to cefiderocol, working to ensure the antibiotic reaches patients in low- and middle-income countries.
• Lixa Pty Ltd.coreStrategic or Co-development PartnerLixa partnered with GARDP to advance Neox-121 to clinical trials for antimicrobial resistance. Lixa raised AU$28 million (US$20 million) in Series B funding to support the drug candidate's progression into clinical development as part of efforts to address the growing global AMR threat.
• DNDi (Drugs for Neglected Diseases initiative)coreStrategic or Co-development PartnerDNDi and GARDP joined forces to accelerate drug development for patients in greatest need. DNDi and GARDP share a joint origin, with GARDP launched by WHO and DNDi in 2016, and GARDP became independent in 2018. The organizations continue to collaborate on research and development programs.
• Medicines for Malaria Venture (MMV)majorStrategic or Co-development PartnerDNDi, GARDP, and MMV joined forces to accelerate drug development for patients in greatest need, combining expertise and resources in global health R&D.
• AntabiomajorStrategic or Co-development PartnerAntabio and GARDP joined forces to identify potential next-generation antibiotics, combining Antabio's expertise in antibiotic development with GARDP's global health focus.
• Tokyo Institute of Technology (東京科学大学)majorStrategic or Co-development PartnerIn July 2025, GARDP and Tokyo Institute of Technology initiated joint research to elucidate the binding structures of proteins and compounds that could lead to new antibiotics for drug-resistant infections.
• CARB-XmajorStrategic or Co-development PartnerThe European Commission invests in CARB-X and GARDP to ramp up global response to antimicrobial resistance. Both organizations receive support from the EU's BARDA co-funded program.
• DebiopharmcoreStrategic or Co-development PartnerGARDP and Debiopharm collaborate on a new gonorrhea antibiotic (zoliflodacin), with Debiopharm providing clinical development support and GARDP focusing on access and public health needs.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• PATH: PATH is a global health non-profit that operates cross-disease product-development programs (vaccines, drugs, devices) for LMICs, often in partnership with WHO and national governments. Its product-development function and public-sector orientation place it in GARDP's direct peer set.
• FIND (Foundation for Innovative New Diagnostics): FIND is a global non-profit PDP that accelerates the development and delivery of diagnostic tests for poverty-related diseases, often co-located in Geneva and sharing WHO/AMR donor ecosystems with GARDP. It functions as a sister PDP in the global health R&D architecture.
• IAVI (International AIDS Vaccine Initiative): IAVI is a PDP focused on HIV vaccines and antibody development, pairing public-sector and philanthropic funding with biotech/pharma partnerships. It is a direct structural peer to GARDP in mission, governance, and go-to-market approach.
• CARB-X: CARB-X is a global non-profit partnership specifically focused on accelerating antibacterial product development to address AMR. GARDP and CARB-X are co-funded by the EU/BARDA program and directly collaborate, making CARB-X a tightly overlapping AMR-specific PDP peer.
• Coalition for Epidemic Preparedness Innovations (CEPI): CEPI is a foundation/Purpose-driven partnership that funds and coordinates vaccine development against epidemic threats. It shares GARDP's PDP funding architecture, public-private coordinating role, and global health mandate targeting populations underserved by commercial markets.
• TB Alliance: TB Alliance is a PDP dedicated to developing and delivering improved tuberculosis treatments, operating via licensing and partnerships with generics manufacturers. It mirrors GARDP's PPP model, public health mission, and LMIC access orientation around a different infectious disease.
• Medicines for Malaria Venture (MMV): MMV is a Product Development Partnership for malaria drugs, jointly working with GARDP and DNDi to 'accelerate drug development for patients in greatest need.' It is structurally identical to GARDP: foundation model, donor-funded, focused on an infectious-disease pipeline serving LMICs.
• Drugs for Neglected Diseases initiative (DNDi): DNDi is the most directly comparable peer: it co-founded GARDP with WHO in 2016, operates the same not-for-profit PDP model, and shares an organizational heritage and joint programs. Both organizations address global health needs that traditional pharmaceutical markets under-serve.

Broad incumbents

• Wellcome Trust: Wellcome Trust is one of the largest global health research funders, with significant AMR programs and grant-making role. While not a single-disease PDP, it is a major ecosystem player and potential funder/partner that addresses overlapping global health R&D needs across a much broader portfolio.
• World Health Organization (WHO): WHO co-founded GARDP with DNDi in 2016 and remains a key convener and policy partner in AMR. As GARDP's institutional parent/convener, WHO operates across all infectious diseases and global health R&D, providing strategic alignment but competing for visibility with other WHO-PDP relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gardp

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Antibiotic Research and Development Partnership (GARDP)